omefas

DRUG3 trials

Sponsors

AstraZeneca

Conditions

HypertriglyceridemiaSevere Hypertriglyceridemia

Phase 1

Interaction of Epanova on Warfarin Pharmacokinetic and Anticoagulant Activity and Comparison of the Effects of Epanova and Lovaza on Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA) After Low-fat Meals

CompletedNCT01431690

AstraZenecaHypertriglyceridemia

Start: 2011-08-31End: 2011-10-31Updated: 2015-04-24

The Effect of Multiple Doses of Epanova® on the Multiple-Dose Pharmacokinetics of Simvastatin in Healthy Normal Subjects

CompletedNCT01486433

AstraZenecaHypertriglyceridemia

Start: 2011-11-30End: 2012-03-31Updated: 2015-04-30

Phase 2

Epanova® for Lowering Very High Triglycerides

CompletedNCT01242527

AstraZenecaSevere Hypertriglyceridemia

Start: 2011-01-31End: 2012-04-30Updated: 2016-08-04

Related Papers

No Effect of Omega-3 Carboxylic Acids on Pharmacokinetics/Pharmacodynamics of Warfarin or on Platelet Function When Co-administered with Acetylsalicylic Acid: Results of Two Phase I Studies in Healthy Volunteers.

2017-06-011 citations

Assessment of pharmacokinetic interaction between omega-3 carboxylic acids and the statins rosuvastatin and simvastatin: Results of 2 phase I studies in healthy volunteers.

2017-04-052 citations

Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: the EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial.

2013-10-14171 citations